期刊文献+

抑郁症患者血清同型半胱氨酸水平的研究 被引量:14

Serum level of homocysteine in depressive patients.
下载PDF
导出
摘要 目的 探讨同型半胱氨酸 (Homocysteine ,Hcy)在抑郁症发病中的作用。方法 采用荧光偏振免疫法 (FPLA)检测 2 2例抑郁症患者 (抑郁症组 )和 2 0名正常人 (对照组 )的血清Hcy水平 ,以 μmol/l计。 结果 抑郁症组血清Hcy水平高于对照组 [(16 .37± 6 .4 5 ) μmol/l比 (11.6 2± 4 .0 7) μmol/l,P <0 .0 1]。抑郁症组高同型半胱氨酸血症 (Hyperhomocysteinemia ,HHcy) (血清Hcy水平 >16 .0 0 μmlo/l)的发生率明显高于对照组 (4 5 .4 5 %比 10 .0 0 % ,oddsratio ,7.5 ;95 %可信区间 ,1.5 9~ 35 .39,P <0 .0 5 )。结论 抑郁症患者的血清Hcy水平升高 ,提示Hcy在抑郁症的发病中起一定作用。 Objective To investigate the association between homocysteine and depression.Methods Serum level of homocysteine was measured in 22 patients with depression and 20 normal controls by fluorescence polarization immunoassay(FPIA).Results Hcy concentration in patient group was significantly higher than that in the control group [(16.37±6.45)μmol/l vs (11.62±4.07)μmol/l,P<0.01].There was a significantly higher incidence of hyperhomocysteinemia(HHcy) in patient group than that in control group(45.45% vs 10.00%,odds ratio,7.5;95% confidence interval,1.59~35.39,P<0.05).Conclusion It is suggested that homocysteine played a role in pathogenesis of depression.
出处 《山东精神医学》 2004年第2期65-66,共2页 Shangdong Archives of Psychiatry
关键词 抑郁症 血清 同型半胱氨酸 HCY 精神卫生 Depression Homocysteine
  • 相关文献

参考文献5

  • 1周爱儒.生物化学(第5版)[M].北京:人民卫生出版社,2001.374-377.
  • 2余月明,侯凡凡,张训,刘俊,胡敏燕,杨凌,许顶立.慢性肾功能衰竭患者的高同型半胱氨酸血症[J].中华肾脏病杂志,2002,18(1):34-37. 被引量:45
  • 3Teodoro Bottiglieri,Malcolm Laundy,Richard Crellin,et al.Homocysteine,folate,methylation,and monoamine metabolism in depression.J Neurol Neurosurg Psychiatry,2000,69:228-232
  • 4McCully KS.Homocysteine and vascular disease.Nature Med,1996,2:386-389
  • 5Bjelland I,Tell GS,Vollset SE,et al.Folate,vitamin B12,homocysteine,and the MTHFR 677C->T polymorphism in anxiety and depression:the Hordaland Homocysteine Study.Arch Gen Psychiatry,2003,60(6):618-626

二级参考文献13

  • 1Jacobsen DW, Gatautis VJ, Green R, et al. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: Sex differences and correlation with cobalamin and folate concentrations in healthy subjects. Clin Chem, 1994, 40:873-881.
  • 2Jacobsen DW. Cardiovascular disorders (risk assessment) . Clin Chem, 1993, 65: 367R-373R.
  • 3Yeun JY. The role of homocysteine in end - stage renal disease.Seminars in Dialysis, 1998, 11: 95-101.
  • 4Nygard O, Norderhaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med, 1997, 337: 230-236.
  • 5Bostom AG, Lathrop L. Hyperhomocysteinemia in end- stage renal disease: prevalence, etiology, and potential relationship to artherosclerotic outcomes. Kidney Int, 1997, 52: 10-20.
  • 6Foley RN, Parfrey PS, Samak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis,1998,32 Suppl 3: 112-119.
  • 7Yu HH, Joubran R, Asmi M, et al. Agreement among four homocysteine assays and results in patients with coronaryatherosclerosis and controls. Clin Chem, 2000, 46: 258-264.
  • 8Hultberg B, Andersson A, Arnadottir M. Reduced, free and total fractions of homocysteine and other thiol compounds in plasma from patients with renal failure. Nephron, 1995, 70: 62-67.
  • 9Bostom AG, Culleton BF. Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephron, 1999, 10: 891-900.
  • 10Moustapha A, Naso A, Nahlawi M, et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation, 1998, 97: 138-141.

共引文献58

同被引文献138

引证文献14

二级引证文献85

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部